RESUMO
No disponible
Assuntos
Humanos , Feminino , Doenças Transmitidas por Alimentos/complicações , Hipotensão/complicações , Anafilaxia/complicações , Hipersensibilidade Imediata/complicações , Pressão Arterial/fisiologia , Diagnóstico DiferencialRESUMO
No disponible
Assuntos
Humanos , Esofagite Eosinofílica/imunologia , Hipersensibilidade/imunologia , Hipersensibilidade Imediata/imunologia , Apresentação Cruzada/imunologia , Fatores de RiscoRESUMO
No disponible
No disponible
Assuntos
Masculino , Adulto , Humanos , Datura stramonium/intoxicação , Intoxicação por Plantas/diagnóstico , Atropina/toxicidade , Escopolamina/toxicidade , Diagnóstico Diferencial , Confusão/etiologiaRESUMO
No disponible
No disponible
Assuntos
Idoso , Humanos , Osteoporose , Atenção Primária à Saúde , Fatores de Risco , Densidade ÓsseaRESUMO
Asthmatic patients receiving antileukotrienes may develop hypereosinophilia as a part of a Churg-Strauss syndrome. It is unclear if this effect is directly related to the administration of antileukotrienes or a consequence of the corticosteroid-sparing effect of antileukotrienes unmasking a Churg-Strauss syndrome. We present a case of hypereosinophilia related to zafirlukast therapy. The patient did not fulfil criteria for Churg-Strauss syndrome. Symptoms and laboratory findings improved after zafirlukast was removed.
Assuntos
Asma/tratamento farmacológico , Síndrome de Churg-Strauss/induzido quimicamente , Antagonistas de Leucotrienos/efeitos adversos , Compostos de Tosil/efeitos adversos , Anti-Inflamatórios não Esteroides/imunologia , Síndrome de Churg-Strauss/diagnóstico , Humanos , Indóis , Masculino , Pessoa de Meia-Idade , Fenilcarbamatos , SulfonamidasRESUMO
No disponible
Assuntos
Humanos , Tabagismo/efeitos adversos , Colite Ulcerativa/prevenção & controleRESUMO
No disponible
Assuntos
Masculino , Adulto , Humanos , Miocardite/diagnóstico , Miocardite/patologia , Transtornos Relacionados ao Uso de Substâncias/complicações , Transtornos Relacionados ao Uso de Substâncias/patologia , N-Metil-3,4-Metilenodioxianfetamina/efeitos adversos , N-Metil-3,4-Metilenodioxianfetamina/análise , N-Metil-3,4-Metilenodioxianfetamina/urina , Dor no Peito/etiologia , Fatores de RiscoRESUMO
OBJECTIVE: To know the osteoponia and osteoporosis prevalence in postmenopausal women determined with broadband ultrasonic attenuation (BUA). DESIGN: Descriptives cross-sectional study of prevalence. SETTING: Salvador Allende Health Center. Valencia, Spain. PARTICIPANTS: A total of 115 postmenopausal women aged 49 at 85 years old was studied, initiated in September to December 2003. Iatrogenic menopause or women with calcium, vitamin D, estrogen replacement therapy, estrogen receptor modulators, and biphosphonates therapy were considered criteria for exclusion. We measured bone mineral density with BUA at right calcaneus. MAIN MEASUREMENTS: We analyzed the age, height, and weight, the result of BUA, tobacco and diuretics consumption and years of amenorrhea. RESULTS: . The prevalence of osteoporosis was 50.4%. Other 29.6% had osteopenia. Of the postmenopausal women with osteoporosis, 27.6% were 70 to 75 years old. The 82.8% of postmenopausal women with osteoporosis were younger than 75 years old. The 66.7% postmenopausal women with body mass index lesser than 25 had osteoporosis. CONCLUSIONS: The osteoporosis prevalence in our patients was greater than other studies (30%). Emphasis may be placed on screening osteoporosis with BUA in primary health care. We suggested that educational community programs should start at an earlier age to identify factors that contribute to maintaining bone mineral density among postmenopausal women.
Assuntos
Doenças Ósseas Metabólicas/epidemiologia , Osteoporose Pós-Menopausa/epidemiologia , Idoso , Idoso de 80 Anos ou mais , Estudos Transversais , Feminino , Humanos , Pessoa de Meia-Idade , Pós-Menopausa , PrevalênciaRESUMO
Objetivo. Estudiar la prevalencia de osteopenia y osteoporosis en mujeres posmenopáusicas mediante ultrasonografía ósea cuantitativa (UOC). Diseño. Estudio descriptivo, transversal, de prevalencia. Emplazamiento. Centro de Salud Salvador Allende. Valencia. Participantes. Se incluyó a 115 mujeres posmenopáusicas de 49-85 años durante los meses de septiembre a noviembre de 2003. Se excluyó a las mujeres con menopausia iatrogénica o que previamente hubieran tomado calcio, vitamina D, terapia hormonal sustitutiva, moduladores estrogénicos o bifosfonatos. A las participantes se les realizó una UOC en el calcáneo derecho. Mediciones. Analizamos la edad, la talla y el peso, el resultado de la UOC, el consumo de tabaco y de diuréticos, y los años de amenorrea. Resultados. La prevalencia de la osteoporosis fue del 50,4%. Otro 29,6% presentaba osteopenia. De las mujeres posmenopáusicas que presentaban osteoporosis, el 27,6% tenía 70-75 años y el 17,2%, 55-60 años. El 82,8% de las mujeres posmenopáusicas con osteoporosis era < 75 años. El 66,7% de las pacientes con un índice de masa corporal < 25 tenía osteoporosis. Conclusiones. La prevalencia de osteoporosis en nuestras pacientes fue mayor que en otros estudios (30%). Insistimos en la necesidad de realizar el cribado de la osteoporosis con UOC en atención primaria. Sugerimos que los programas de educación comunitaria deberían comenzar en edades más tempranas para identificar los factores que contribuyen a mantener la densidad mineral ósea en las mujeres posmenopáusicas
Objective. To know the osteoponia and osteoporosis prevalence in postmenopausal women determined with broadband ultrasonic attenuation (BUA). Design. Descriptives cross-sectional study of prevalence. Setting. Salvador Allende Health Center. Valencia, Spain. Participants. A total of 115 postmenopausal women aged 49 at 85 years old was studied, initiated in September to December 2003. Iatrogenic menopause or women with calcium, vitamin D, strogen replacement therapy, estrogen receptor modulators, and biphosphonates therapy were considerated criteria for exclusion. We measured bone mineral density with BUA at right calcaneus. Main mesurements. We analized the age, height, and weight, the result of BUA, tobacco and diuretics consumption and years of amenorrhea. Results. The prevalence of osteoporosis was 50.4%. Other 29.6% had osteopenia. Of the postmenopausal women with osteoporosis, 27.6% were 70 to 75 years old. The 82.8% of postmenopausal women with osteoporosis were younger than 75 years old. The 66.7% postmenopausal women with body mass index lesser than 25 had osteoporosis. Conclusions. The osteoporosis prevalence in our patients was greater than other studies (30%). Emphasis may be placed on screening osteoporosis with BUA in primary health care. We suggested that educational community programs should start at an earlier age to identificate factors that contribute to maintaining bone mineral density among postmenopausal women
Assuntos
Feminino , Idoso , Idoso de 80 Anos ou mais , Pessoa de Meia-Idade , Humanos , Doenças Ósseas Metabólicas/epidemiologia , Osteoporose Pós-Menopausa/epidemiologia , Estudos Transversais , Pós-Menopausa , PrevalênciaRESUMO
Los ordenadores de bolsillo o PDAs (personal digital assistants) constituyen una alternativa a las clásicas agendas y libros de notas que todos hemos utilizado en medicina. Permiten además disponer de documentación actualizada, recoger información "in situ" e incluso trasmitirla a distancia en el momento. En este artículo se revisan los principales sistemas operativos, las aplicaciones más útiles en medicina y las utilidades disponibles para Alergología
Pocket computers or PDAs (personal digital assistants) are an alternative to the classic agendas and paper and pencil note books that have been worldwide used in medicine. Their technology permit the storage of revised information as well as to file data from patients and even to transmit it to central operation centres in real time. In this article we revise the main operating systems, useful applications in medicine and available utilities in allergy
